Xiao Qingqing, Li Xiaotong, Li Yi, Wu Zhenfeng, Xu Chenjie, Chen Zhongjian, He Wei
School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Key Laboratory of Modern Preparation of TCM, Ministry of Education, Jiangxi University of Traditional Chinese Medicine, Nanchang 330004, China.
Acta Pharm Sin B. 2021 Apr;11(4):941-960. doi: 10.1016/j.apsb.2020.12.018. Epub 2020 Dec 31.
The initiation and development of major inflammatory diseases, , cancer, vascular inflammation, and some autoimmune diseases are closely linked to the immune system. Biologics-based immunotherapy is exerting a critical role against these diseases, whereas the usage of the immunomodulators is always limited by various factors such as susceptibility to digestion by enzymes , poor penetration across biological barriers, and rapid clearance by the reticuloendothelial system. Drug delivery strategies are potent to promote their delivery. Herein, we reviewed the potential targets for immunotherapy against the major inflammatory diseases, discussed the biologics and drug delivery systems involved in the immunotherapy, particularly highlighted the approved therapy tactics, and finally offer perspectives in this field.
主要炎症性疾病，如癌症、血管炎症和一些自身免疫性疾病的发生和发展与免疫系统密切相关。基于生物制剂的免疫疗法在对抗这些疾病中发挥着关键作用，而免疫调节剂的使用总是受到各种因素的限制，如易被酶消化、难以穿透生物屏障以及被网状内皮系统快速清除。药物递送策略有助于促进它们的递送。在此，我们综述了针对主要炎症性疾病的免疫治疗潜在靶点，讨论了免疫治疗中涉及的生物制剂和药物递送系统，特别强调了已获批的治疗策略，最后对该领域进行了展望。
